摘要
目的:探讨lncRNA DLGAP1-AS2对非小细胞肺癌(NSCLC)A549细胞增殖和凋亡的影响及分子机制。方法:选取49例肺癌患者的癌组织及癌旁组织,RT-qPCR检测DLGAP1-AS2和miR-1193的表达水平;将A549细胞分为si-DLGAP1-AS2组、si-NC组、miR-1193组、miR-NC组、si-DLGAP1-AS2+anti-miR-1193组、si-DLGAP1-AS2+anti-miR-NC组;MTT法、克隆形成实验及流式细胞术分别检测细胞活性、克隆形成数及细胞凋亡率;双荧光素酶报告实验检测DLGAP1-AS2和miR-1193的靶向关系。结果:NSCLC组织中DLGAP1-AS2表达水平高于癌旁组织,miR-1193表达水平低于癌旁组织(P<0.05)。抑制DLGAP1-AS2表达或过表达miR-1193,A549细胞的活性降低,克隆形成数减少,A549细胞凋亡率升高(P<0.05)。DLGAP1-AS2靶向调控miR-1193;干扰miR-1193表达可减弱抑制DLGAP1-AS2表达对NSCLC A549细胞增殖和凋亡的作用。结论:抑制lncRNA DLGAP1-AS2表达可能通过靶向上调miR-1193抑制NSCLC A549细胞增殖,并促进其凋亡。
Objective:To explore the effect of lncRNA DLGAP1-AS2 on proliferation and apoptosis of non-small cell lung cancer(NSCLC)A549 cells and its molecular mechanism.Methods:Cancer tissues and adjacent tissues of 49 lung cancer patients were selected,and expression levels of DLGAP1-AS2 and miR-1193 were detected by RT-qPCR;A549 cells were divided into si-DLGAP1-AS2 group,si-NC group,miR-1193 group,miR-NC group,si-DLGAP1-AS2+anti-miR-1193 group,si-DLGAP1-AS2+anti-miR-NC group;MTT method,clone formation experiment and flow cytometry were used to detect cell viability,number of clone formation and cell apoptosis rate;dual luciferase reporter experiment detected DLGAP1-AS2 and miR-1193 targeting relationship.Results:Expression level of DLGAP1-AS2 in NSCLC tissue was higher than that in adjacent tissue,and expression level of miR-1193 was lower than that in adjacent tissue(P<0.05).Inhibiting expression of DLGAP1-AS2 or overexpressing miR-1193,A549 cell activity was decreased,the number of clones formed was decreased,and A549 cell apoptotic rate was increased(P<0.05).DLGAP1-AS2 targeted and regulated miR-1193;interference with miR-1193 expression could reduce the effect of inhibiting DLGAP1-AS2 expression on proliferation and apoptosis of NSCLC A549 cells.Conclusion:Inhibiting expression of lncRNA DLGAP1-AS2 may inhibit proliferation of NSCLC A549 cell and promote apoptosis by targeting up-regulation of miR-1193.
作者
曹淑琴
朱朝勇
陈维英
祁永花
张晓媛
徐建国(指导)
CAO Shuqin;ZHU Chaoyong;CHEN Weiying;QI Yonghua;ZHANG Xiaoyuan;XU Jianguo(The Second Ward,Department of Oncology,Qinghai Red Cross Hospital,Xining 810000,China)
出处
《中国免疫学杂志》
CAS
CSCD
北大核心
2022年第19期2366-2370,共5页
Chinese Journal of Immunology
基金
青海省卫生和计划生育委员会指导性科研项目(2018-wjzdx-12)。